TSTickerStar
Company alerts/MPLT
MPLT company alerts

MPLT updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for MPLT. Subscribe to MPLT alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent MPLT alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Debt offeringSEC filing

MapLight enters $100,000,000 ATM common stock sales agreement

MapLight entered into a sales agreement with Leerink Partners LLC allowing the company to offer and sell voting common stock from time to time with an aggregate offering price of up to $100,000,000. Leerink will receive a commission of up to 3.0% of the aggregate gross sales price per share sold, and MapLight has no obligation to sell the shares and may suspend offers or terminate the agreement.

Read source-backed brief
SEC filingSEC filing

MPLT 10-Q filed 2026-11-16 | Key takeaways

MPLT filed its 10-Q; the most relevant disclosure change is added August 2026 Private Placement: On August 13, 2026, the Company entered into a Securities Purchase Agreement with certain institutional investors and closed the 2026 Private Placement on August 14, 2026, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 s.

Read source-backed brief
Equity offeringSEC filing

MapLight Reports Q3 2026 Net Loss of $51.6M, Advances ZEPHYR-2 Phase 3 Trial Planning

MapLight Therapeutics reported Q3 2026 net loss of $51.6 million versus $29.4 million in Q3 2025, with R&D expenses increasing to $44.2 million from $27.1 million year-over-year due to clinical trial advancement and increased employee-related costs including stock-based compensation. The company ended Q3 2026 with $463.4 million in cash, cash equivalents and investments, expected to fund operations through 2028. The company initiated start-up activities for ZEPHYR-2, its planned Phase 3 trial of ML-007C-MA in sc...

Read source-backed brief